Tissue microarray studies in bladder cancer

References

• Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4–34
   PubMed Web of Science ®Google Scholar
• Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology 2008; 71: 131–5
   PubMed Web of Science ®Google Scholar
• Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 2006; 27: 361–73
   PubMed Web of Science ®Google Scholar
• Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 9: 713–25
   Google Scholar
• Eble JN, Sauter G, Epstein JI, Sesterhenn IAE. Pathology and genetics of tumours of the urinary system and male genital organs. In: World Health Organization classification of tumours. Lyon: IARC Press; 2004.
   Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844–7
   PubMed Web of Science ®Google Scholar
• Schoenberg-Fejzo M, Slamon DJ. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol 2001; 159: 1645–50
   PubMed Web of Science ®Google Scholar
• Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev 2003;2.
   Google Scholar
• Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, Forster T, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001; 194: 349–57
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008; 18: 1–8
   PubMed Web of Science ®Google Scholar
• Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur Urol 2000; 38: 691–9
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005; 6: 678–86
   PubMed Web of Science ®Google Scholar
• Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005; 65: 767–79
   PubMed Web of Science ®Google Scholar
• Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 2007; 13: 488–97
   PubMed Web of Science ®Google Scholar
• Shariat F, Zlotta A, Ashfaq R, Sagalowsky A, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer develop and biologic aggressiveness. Mod Pathol 2007; 20: 445–50
   PubMed Web of Science ®Google Scholar
• Karam J, Lotan Y, Karakiewicz P, Ashfaq R, Sagalowsky A, Roehrborn C, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128–36
   PubMed Web of Science ®Google Scholar
• Baumgart E, Cohen M, Neta B, Jacobs M, Wotkowicz C, Rieger-Christ K, et al. Identification and prognostic significance of an epithelial–mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007; 13: 1685–94
   PubMed Web of Science ®Google Scholar
• Gomez-Roman J, Saenz P, Conzalez J, Escuredo K, Cruz S, Junquera C, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005; 11: 459–65
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Fischer G, Alvarez V, Ahmed A, Herrmann F. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int 2007; 100: 1182–7
   PubMed Web of Science ®Google Scholar
• Wild PJ, Kunz-Schughart L, Stoehr R, Burger M, Blaszyk H, Simon R, et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 2005; 27: 385–91
   PubMed Web of Science ®Google Scholar
• Margulis V, Shariat S, Ashfaq R, Sagalowsky A, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006; 12: 7369–73
   PubMed Web of Science ®Google Scholar
• Van Oers JMM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade non-invasive urothelial bladder tumours. Eur Urol 2007; 52: 760–8
   PubMed Web of Science ®Google Scholar
• Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, et al. Gene expression profiling of progressive papillary non-invasive carcinomas of the urinary bladder. Clin Cancer Res 2005; 11: 4415–29
   PubMed Web of Science ®Google Scholar
• Blaveri E, Simko J, Korkola J, Brewer J, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11: 4044–55
   PubMed Web of Science ®Google Scholar
• Kim J, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 2005; 85: 532–49
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Socci N, Lozano J, Haab B, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am J Pathol 2006; 168: 93–103
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Socci N, Richstone L, Corton M, Behrendt N, Wulkfuhle J, et al. Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. Am J Pathol 2007; 171: 1650–8
   PubMed Web of Science ®Google Scholar
• Brown L, Huntsman D. Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J Mol Hist 2007; 38: 151–7
   PubMed Web of Science ®Google Scholar
• Schraml P, Kononen J, Bubendorf L, Moch H, Bissing H, Nocito A, et al. Tissue Microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966–75
   PubMed Web of Science ®Google Scholar
• Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000; 157: 787–94
   PubMed Web of Science ®Google Scholar
• Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 2001; 61: 4514–9
   PubMed Web of Science ®Google Scholar
• Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GL1) in urinary bladder cancer. Oncogene 2002; 21: 2476–83
   PubMed Web of Science ®Google Scholar
• Zaharieva B, Simon R, Diener P, Achermann D, Maurer R, Alund F, et al. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 2003; 201: 603–8
   PubMed Web of Science ®Google Scholar
• Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004; 23: 5616–23
   PubMed Web of Science ®Google Scholar
• Zheng M, Simon R, Mirlacher M, Maurer R, Gasser T, Forster T, et al. TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol 2004; 165: 63–9
   PubMed Web of Science ®Google Scholar
• Zaharieva B, Simon R, Ruiz C, Oeggerli M, Mihatsch M, Gasser T, et al. High-throughput tissue microarray analysis of CMYC amplification in urinary bladder cancer. Int J Cancer 2005; 117: 952–6
   PubMed Web of Science ®Google Scholar
• Oeggerli M, Schraml P, Ruiz C, Bloch M, Novotny H, Mirlacher M, et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 2006; 25: 6538–43
   PubMed Web of Science ®Google Scholar
• Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, et al. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clin Cancer Res 2008; 14: 2527–34
   PubMed Web of Science ®Google Scholar
• Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004; 84: 465–78
   PubMed Web of Science ®Google Scholar
• Schwarz S, Rechenmacher M, Filbeck T, Knuechel R, Blaszyk H, Hartmann A, et al. Value of multicolor fluorescence in situ hybridization (UroVysion-TM) in the differential diagnosis of flat urothelial lesions. J Clin Pathol 2008; 61: 272–7
   PubMed Web of Science ®Google Scholar